<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children - Kew, KM - 2013 | Cochrane Library</title> <meta content="Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children - Kew, KM - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009019.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children - Kew, KM - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009019.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009019.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children" name="citation_title"/> <meta content="Kayleigh M Kew" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="kkew@sgul.ac.uk" name="citation_author_email"/> <meta content="Charlotta Karner" name="citation_author"/> <meta content="BMJ" name="citation_author_institution"/> <meta content="Stephanie M Mindus" name="citation_author"/> <meta content="Karolinska University Hospital Solna" name="citation_author_institution"/> <meta content="Giovanni Ferrara" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD009019.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/12/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009019.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009019.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009019.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Asthmatic Agents [*administration &amp; dosage]; Asthma [*drug therapy]; Bronchodilator Agents [*administration &amp; dosage]; Budesonide [*administration &amp; dosage]; Drug Combinations; Ethanolamines [*administration &amp; dosage]; Formoterol Fumarate; Maintenance Chemotherapy [methods]; Nebulizers and Vaporizers; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009019.pub2&amp;doi=10.1002/14651858.CD009019.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="QzbxnhyM";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009019\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009019\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009019.pub2",title:"Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children",firstPublishedDate:"Dec 16, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009019.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009019.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009019.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009019.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009019.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009019.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009019.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009019.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009019.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009019.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8980 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009019.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-sec-0023"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-sec-0024"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/appendices#CD009019-sec-0093"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/table_n/CD009019StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/table_n/CD009019StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/information#CD009019-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Kayleigh M Kew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/information#CD009019-cr-0003">Charlotta Karner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/information#CD009019-cr-0004">Stephanie M Mindus</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009019.pub2/information#CD009019-cr-0005">Giovanni Ferrara</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/information/en#CD009019-sec-0103">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 December 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009019.pub2">https://doi.org/10.1002/14651858.CD009019.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009019-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009019-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009019-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009019-abs-0005">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009019-abs-0001" lang="en"> <section id="CD009019-sec-0001"> <h3 class="title" id="CD009019-sec-0001">Background</h3> <p>Asthma is characterised by chronic inflammation of the airways and recurrent exacerbations with wheezing, chest tightness and cough. Treatment with inhaled steroids and bronchodilators often results in good control of symptoms, prevention of further morbidity and mortality and improved quality of life. Several steroids and beta<sub>2</sub>‐agonists (long‐ and short‐acting) as well as combinations of these treatments are available in a single inhaler to be used once or twice a day, with a separate inhaler for relief of symptoms when needed (for patients in Step three or higher, according to Global Initiative for Asthma (GINA) guidelines). Budesonide/formoterol is also licenced for use as maintenance and reliever therapy from a single inhaler (SiT; sometimes referred to as SMART therapy). SiT can be prescribed at a lower dose than other combination therapy because of the additional steroid doses being received as reliever therapy. It has been suggested that using SiT improves compliance and hence reduces symptoms and exacerbations, but it is unclear whether it increases side effects associated with the use of inhaled steroids. </p> </section> <section id="CD009019-sec-0002"> <h3 class="title" id="CD009019-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of budesonide/formoterol in a single inhaler (SiT) to be used for both maintenance and reliever therapy in asthma in comparison with maintenance treatment provided through combination inhalers with a higher maintenance steroid dose (either fluticasone/salmeterol or budesonide/formoterol), along with additional fast‐acting beta<sub>2</sub>‐agonists for relief of symptoms. </p> </section> <section id="CD009019-sec-0003"> <h3 class="title" id="CD009019-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register of trials, online trial registries and drug company websites. The most recent search was conducted in November 2013. </p> </section> <section id="CD009019-sec-0004"> <h3 class="title" id="CD009019-sec-0004">Selection criteria</h3> <p>We included parallel‐group, randomised controlled trials of at least 12 weeks' duration. Studies were included if they compared single‐inhaler therapy with budesonide/formoterol (SiT) versus combination inhalers at a higher maintenance dose of steroids than was given in the SiT arm (either salmeterol/fluticasone or budesonide/formoterol). </p> </section> <section id="CD009019-sec-0005"> <h3 class="title" id="CD009019-sec-0005">Data collection and analysis</h3> <p>We used standard methods expected by The Cochrane Collaboration. Primary outcomes were exacerbations requiring hospitalisation, exacerbations requiring oral corticosteroids and serious adverse events (including mortality). </p> </section> <section id="CD009019-sec-0006"> <h3 class="title" id="CD009019-sec-0006">Main results</h3> <p>Four studies randomly assigning 9130 people with asthma were included; two were six‐month double‐blind studies, and two were 12‐month open‐label studies. No trials included children younger than age 12. Trials included more women than men, with mean age ranging from 38 to 45, and mean baseline steroid dose (inhaled beclomethasone (BDP) equivalent) from 636 to 888 μg. Mean baseline forced expiratory volume in one second (FEV<sub>1</sub>) percentage predicted was between 70% and 73% in three of the trials, and 96% in another. All studies were funded by AstraZeneca and were generally free from methodological biases, although the two open‐label studies were rated as having high risk for blinding, and some evidence of selective outcome reporting was found. These possible sources of bias did not lead us to downgrade the quality of the evidence. The quantity of inhaled steroids, including puffs taken for relief from symptoms, was consistently lower for SiT than for the comparison groups. </p> <p>Separate data for exacerbations leading to hospitalisations, to emergency room (ER) visits or to a course of oral steroids could not be obtained. Compared with higher fixed‐dose combination inhalers, fewer people using SiT had exacerbations requiring hospitalisation or a visit to the ER (odds ratio (OR) 0.72, 95% confidence interval (CI) 0.57 to 0.90; I<sup>2</sup> = 0%, P = 0.66), and fewer had exacerbations requiring a course of oral corticosteroids (OR 0.75, 95% CI 0.65 to 0.87; I<sup>2</sup> = 0%, P = 0.82). This translates to one less person admitted to hospital or visiting the ER (95% CI 0 to 2 fewer) and two fewer people needing oral steroids (95% CI 1 to 3 fewer) compared with fixed‐dose combination treatment with a short‐acting beta‐agonist (SABA) reliever (per 100 treated over eight months). No statistical heterogeneity was observed in either outcome, and the evidence was rated of high quality. Although issues with blinding were evident in two of the studies, and one study recruited a less severe population, sensitivity analyses did not change the main results, so quality was not downgraded. </p> <p>We could not rule out the possibility that SiT increased rates of serious adverse events (OR 0.92, 95% CI 0.74 to 1.13; I<sup>2</sup> = 0%, P = 0.98; moderate‐quality evidence, downgraded owing to imprecision). </p> <p>We were unable to say whether SiT improved results for several secondary outcomes (morning and evening peak expiratory flow (PEF), rescue medication use, symptoms scales), and in cases where results were significant, the effect sizes were not considered clinically meaningful (predose FEV<sub>1</sub>, nocturnal awakenings and quality of life). </p> </section> <section id="CD009019-sec-0007"> <h3 class="title" id="CD009019-sec-0007">Authors' conclusions</h3> <p>SiT reduces the number of people having asthma exacerbations requiring oral steroids and the number requiring hospitalisation or an ER visit compared with fixed‐dose combination inhalers. Evidence for serious adverse events was unclear. The mean daily dose of inhaled corticosteroids (ICS) in SiT, including the total dose administered with reliever use, was always lower than that of the other combination groups. This suggests that the flexibility in steroid administration that is possible with SiT might be more effective than a standard fixed‐dose combination by increasing the dose only when needed and keeping it low during stable stages of the disease. Data for hospitalisations alone could not be obtained, and no studies have yet addressed this question in children younger than age 12. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009019-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009019-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009019-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009019-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009019-abs-0002" lang="en"> <h3>For people with chronic asthma, is a single combination inhaler for both regular and "as‐needed" treatment better than two separate inhalers? </h3> <p><b>Background for the review</b> <br/> Asthma is a chronic inflammation of the airways that causes flare‐ups of wheezing, chest tightness and coughing. Treatment with inhaled steroids and other inhaled drugs that relax the airways (bronchodilators) often gives good control of symptoms, prevents serious flare‐ups and improves quality of life. Several steroids and bronchodilators (long‐ and short‐acting) as well as combinations of these treatments are available in a single inhaler. </p> <p>This review focusses on a particular inhaled therapy called 'single‐inhaler therapy' (SiT), sometimes called SMART therapy. The idea is that the SiT is taken once or twice a day and also anytime it is needed for relief of symptoms. In theory, this improves compliance, controls asthma symptoms and prevents exacerbations while allowing lower overall exposure to inhaled steroids. The drugs contained in SiT are budesonide and formoterol. </p> <p>This review aimed to find out whether SiT is as safe and effective as a combination inhaler (containing a steroid and a long‐acting beta‐agonist (LABA)) plus another inhaler for relief of symptoms. The review looked at the effects of these treatments for adults and children with chronic asthma. </p> <p><b>What did we find?</b> <br/> Four studies including 9130 adults and adolescents were included. None of the studies included children younger than age 12. The studies lasted for six months to a year, and all were funded by one drug company. Studies included more women than men, with average age of about 40. Three studies recruited people with quite similar symptoms, but one study included people with less severe asthma. The studies were well conducted, although two did not hide which treatments were being taken (known as blinding), which might have affected the results. The amount of inhaled steroids, including puffs taken for relief from symptoms, was consistently lower for SiT than for the comparison groups using two types of inhalers. Overall, we believe that the quality of the evidence was high to moderate. </p> <p><b>Main findings</b> <br/> Fewer people taking SiT had flare‐ups that needed a hospital stay or a visit to the ER (one fewer per 100 treated than in the control group, 95% CI 0 to 2 fewer) or a course of oral steroids (two fewer per 100 treated, 95% CI one to three fewer). If more studies are published, it is unlikely that our opinions on these main findings will change. However, we could not tell whether one treatment caused more serious adverse events than the other. </p> <p><b>Other findings</b> <br/> SiT had a small benefit on one measure of lung function (predose forced expiratory volume in one second (FEV<sub>1</sub>)). However, for several other measures, not enough information was available to show which treatment was better (amount of medication taken on an 'as needed' basis, various symptom measures and quality of life). </p> <p>In conclusion, SiT reduces the need for a hospital stay or an ER visit and for courses of oral steroids for asthma flare‐ups. SiT did not increase the quantity of inhaled steroids taken overall, and it was unclear whether it increases or decreases serious side effects. Currently no data are available for the use of SiT in children younger than age 12. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009019-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009019-sec-0088"></div> <h3 class="title" id="CD009019-sec-0089">Implications for practice</h3> <section id="CD009019-sec-0089"> <p>This review provides evidence of high and moderate quality showing that SiT reduces exacerbations requiring hospitalisation or an ER visit and courses of oral steroids. Current evidence is insufficient to show whether SiT is associated with more or fewer serious adverse events compared with higher fixed‐dose ICS/LABA combinations, and no data were available for exacerbations leading to hospitalisation. The mean daily dose of ICS in SiT, including the total dose administered with reliever use, was always lower than that of the other combination groups. This suggests that the flexibility in steroid administration that is possible with SiT might be more effective than a standard fixed‐dose combination by increasing the dose only when needed and keeping it low during stable stages of the disease. </p> </section> <h3 class="title" id="CD009019-sec-0090">Implications for research</h3> <section id="CD009019-sec-0090"> <p>Research into this comparison should be aimed at children and adolescents with persistent asthma, particularly children younger than age 12, for whom no evidence is currently available. Researchers should report the number of people with the most severe exacerbations—those requiring admission to hospital—as distinct from the number with exacerbations leading to systemic medications and ER visits. Future studies might consider better characterising participants who are likely to benefit from SiT using different fixed doses of ICS combined with the LABA, to optimise the approach for participants with different severities of asthma. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009019-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009019-sec-0015"></div> <div class="table" id="CD009019-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">SiT for maintenance/relief compared with higher‐dose ICS/LABA + SABA for chronic asthma in adults and children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>SIT for maintenance/relief compared with ICS/LABA combination at a higher fixed dose + SABA for chronic asthma in adults and children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Studies recruited adults and adolescents aged 12 and older with chronic asthma<br/> <b>Intervention:</b> SiT for maintenance and relief<br/> <b>Comparison:</b> higher‐dose ICS/LABA as maintenance + SABA as relief </p> <p><b>Setting</b>: community </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> <p><b>Follow‐up calculated as weighted means, with range</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Overall heterogeneity and subgroup differences (ICS/LABA combination in control group)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Higher‐dose ICS/LABA+ SABA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SiT for maintenance/relief</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>People with exacerbations requiring hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AstraZeneca could not provide data for hospitalisations separate to ER visits</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Patients with exacerbations requiring oral steroids</b> <br/> Follow‐up: eight months (six to 12) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Eight per 100</b> </p> <p>(seven to nine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.75</b> </p> <p>(0.65 to 0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9096</p> <p>(four studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I<sup>2</sup> = 0%; P value 0.82 </p> <p>Subgroup differences (P value 0.45)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with serious adverse events</b> <br/> Follow‐up: eight months (six to 12) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Four per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Four per 100</b> <br/> (three to five) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.92</b> <br/> (0.74 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9130<br/> (four studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I<sup>2</sup> = 0%; P value 0.98 </p> <p>Subgroup differences (P value 0.88)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with severe exacerbations (requiring hospitalisation <i>or</i> ER visit)</b> <br/> Follow‐up: eight months (six to 12) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Five per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Four per 100</b> <br/> (three to five) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.72</b> <br/> (0.57 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7768<br/> (three studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I<sup>2</sup> = 0%; P value 0.66 </p> <p>Subgroup differences (P value 0.21)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; <b>ICS/LABA:</b> inhaled corticosteroid/long‐acting beta<sub>2</sub>‐agonist combination inhaler; <b>SABA:</b> short‐acting beta<sub>2</sub>‐agonist; <b>SiT:</b> single‐inhaler therapy with budesonide/formoterol inhaler. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Wide confidence intervals, downgraded once for imprecision.</p> <p>Although issues with blinding were noted in two of the studies, and one study recruited a less severe population, sensitivity analyses did not change the main results, so outcomes were not downgraded. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009019-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009019-sec-0016"></div> <section id="CD009019-sec-0017"> <h3 class="title" id="CD009019-sec-0017">Description of the condition</h3> <p>Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role (<a href="./references#CD009019-bbs2-0032" title="GINA . Global strategy for asthma management and prevention. http://www.ginasthma.org/ (accessed 10 March 2013). ">GINA 2012</a>). An unequivocal clinical definition of asthma has not been determined, although it is postulated that in all forms of asthma, chronic inflammation is associated with bronchial hyperresponsiveness, leading to recurrent episodes of wheezing, breathlessness, cough and chest tightness, especially during the night and early in the morning. Wide variations in age of onset, symptoms, triggers, association with allergic disease and type of inflammatory cell infiltrate have been seen in patients diagnosed with asthma, underlying the probable existence of more than one pathophysiological process. Patients with all forms and severity of disease typically have intermittent symptoms of cough, wheeze and/or breathlessness. Underlying these symptoms is a process of variable and at least partially reversible airway obstruction, airway hyperresponsiveness and (with the possible exception of solely exercise‐induced asthma) chronic inflammation. </p> </section> <section id="CD009019-sec-0018"> <h3 class="title" id="CD009019-sec-0018">Description of the intervention</h3> <section id="CD009019-sec-0019"> <h4 class="title">Single‐inhaler therapy (SiT)</h4> <p>Asthma therapy is based on modulation of airways inflammation, which is the main cause of symptoms and exacerbations. This is not necessary for people with very mild and intermittent asthma, as symptoms can be well controlled with a short‐acting beta<sub>2</sub>‐agonist (SABA) as relief (Step one; <a href="./references#CD009019-bbs2-0032" title="GINA . Global strategy for asthma management and prevention. http://www.ginasthma.org/ (accessed 10 March 2013). ">GINA 2012</a>). People with persistent asthma can use preventer therapy (usually low‐dose inhaled corticosteroid (ICS)) to maintain symptom control, improve lung function and reduce the need for emergency care by modulating airways inflammation (Step two; <a href="./references#CD009019-bbs2-0032" title="GINA . Global strategy for asthma management and prevention. http://www.ginasthma.org/ (accessed 10 March 2013). ">GINA 2012</a>). Combination therapy with a long‐acting beta<sub>2</sub>‐agonist (LABA) and ICS is regularly used to maintain control in patients with persistent/chronic asthma not achieving good control of symptoms and exacerbations with low‐dose ICS alone, and it is often used with an additional short‐acting inhaler when needed (Step three; <a href="./references#CD009019-bbs2-0032" title="GINA . Global strategy for asthma management and prevention. http://www.ginasthma.org/ (accessed 10 March 2013). ">GINA 2012</a>). Some people might need a medium to high dose of ICS combined with LABA (Step four; <a href="./references#CD009019-bbs2-0032" title="GINA . Global strategy for asthma management and prevention. http://www.ginasthma.org/ (accessed 10 March 2013). ">GINA 2012</a>). This step‐wise approach allows practitioners to tailor the use of ICS and combinations to the severity of asthma in different patients, thereby avoiding excessive exposure to steroids and their long‐term side effects (<a href="./references#CD009019-bbs2-0032" title="GINA . Global strategy for asthma management and prevention. http://www.ginasthma.org/ (accessed 10 March 2013). ">GINA 2012</a>). One particular combination inhaler containing budesonide (ICS) and formoterol (LABA) has the potential to be used for both maintenance and reliever therapy; this enables patients and doctors to increase the dose of both medications simultaneously, with some flexibility when asthma symptoms worsen. This is known as single‐inhaler therapy (SiT), or SMART therapy—referred to as SiT throughout this review. SiT can be prescribed at a lower dose than other ICS/LABA combination therapy because of the additional ICS being received as reliever therapy. This might allow asthma symptoms to be controlled and exacerbations to be prevented with lower overall exposure to inhaled steroids. It has been suggested that using one inhaler in this way for both maintenance and reliever therapy could also be more effective by improving compliance, but it is unclear whether it increases side effects associated with the use of inhaled steroids. </p> </section> <section id="CD009019-sec-0020"> <h4 class="title">Combination therapy with separate short‐acting bronchodilator</h4> <p>The two commonly used combination inhalers are budesonide and formoterol, and fluticasone and salmeterol. The LABA, salmeterol, has a relatively slow onset of bronchodilation (<a href="./references#CD009019-bbs2-0040" title="PalmqvistM , ArvidssonP , BeckmanO , PetersonS , LotvallJ . Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulmonary Pharmacology and Therapeutics2001;14(1):29‐34. ">Palmqvist 2001</a>), and it is not licenced for use on an 'as‐needed' basis; this means that salmeterol and fluticasone can be used only for maintenance therapy, and a separate SABA is needed for additional symptom relief. Reliever medication with SABAs such as salbutamol and terbutaline, or formoterol (a fast‐acting but longer‐lasting formulation), is licenced for this purpose (<a href="./references#CD009019-bbs2-0022" title="British Thoracic Society/ Scottish Intercolleate Guideline Network. British Guidelines on the Management of Asthma [revised January 2012]. http://www.sign.ac.uk/ (accessed 5 September 2012). ">BTS/SIGN 2012</a>). Budesonide and formoterol combinations can be used alongside SABAs in this way. </p> </section> </section> <section id="CD009019-sec-0021"> <h3 class="title" id="CD009019-sec-0021">How the intervention might work</h3> <p>The combination of ICS and LABA in a single inhaler is an effective way of delivering maintenance anti‐inflammatory and bronchodilator therapy in chronic asthma (<a href="./references#CD009019-bbs2-0033" title="GreenstoneIR , Ni ChroininMN , MasseV , DanishA , MagdalinosH , ZhangX , et al. Combination of inhaled long‐acting beta2‐agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD005533] ">Greenstone 2005</a>; <a href="./references#CD009019-bbs2-0039" title="Ni ChroininM , GreenstoneIR , DanishA , MagdolinosH , MasseV , ZhangX , et al. Long‐acting beta2‐agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database of Systematic Reviews2005, Issue 4. [DOI: 10.1002/14651858.CD005535] ">Ni Chroinin 2005</a>). The anti‐inflammatory properties of the ICS and the bronchodilatory effect of the LABA play complementary roles in reducing inflammation in the airways and improving lung function with relief of symptoms related to bronchospasm (<a href="./references#CD009019-bbs2-0017" title="AdamsNP , BestallJC , LassersonTJ , JonesPW , CatesCJ . Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4] ">Adams 2008</a>; <a href="./references#CD009019-bbs2-0044" title="WaltersEH , GibsonPG , LassersonTJ , WaltersJAE . Long‐acting beta2‐agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001385.pub2] ">Walters 2007</a>). Both are recommended when low‐dose ICS alone is not sufficient to control asthma, which is stated at Step three in the British asthma guidelines (<a href="./references#CD009019-bbs2-0022" title="British Thoracic Society/ Scottish Intercolleate Guideline Network. British Guidelines on the Management of Asthma [revised January 2012]. http://www.sign.ac.uk/ (accessed 5 September 2012). ">BTS/SIGN 2012</a>). Concerns have been raised about the use of single‐inhaler LABA in chronic asthma, in particular when it is used without a regular ICS, in relation to the possible increased risk of severe adverse events and asthma‐related death (<a href="./references#CD009019-bbs2-0023" title="CatesCJ , CatesMJ , LassersonTJ . Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD006923.pub2] ">Cates 2008</a>; <a href="./references#CD009019-bbs2-0024" title="CatesCJ , CatesMJ . Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006363.pub2] ">Cates 2008a</a>; <a href="./references#CD009019-bbs2-0044" title="WaltersEH , GibsonPG , LassersonTJ , WaltersJAE . Long‐acting beta2‐agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001385.pub2] ">Walters 2007</a>). The flexibility in steroid administration that is possible with SiT might be more effective than a standard fixed‐dose combination, allowing steroid dose to be increased as a reliever when needed while keeping the maintenance dose low when the disease is stable. </p> </section> <section id="CD009019-sec-0022"> <h3 class="title" id="CD009019-sec-0022">Why it is important to do this review</h3> <p>It is recognised that many patients who are prescribed ICS do not continue to take the treatment in clinical practice, and combination inhalers can increase ICS use both as daily maintenance therapy with a SABA inhaler for relief (<a href="./references#CD009019-bbs2-0029" title="DeleaTE , HagiwaraM , StanfordRH , StempelDA . Effects of fluticasone propionate/salmeterol combination on asthma‐related health care resource utilization and costs and adherence in children and adults with asthma. Clinical Therapeutics2008;30(3):560‐71. ">Delea 2008</a>) and as single‐inhaler therapy (SiT) (<a href="./references#CD009019-bbs2-0043" title="SovaniMP , WhaleCI , OborneJ , CooperS , MortimerK , EkströmT , et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. British Journal of General Practice2008;58(546):37‐43. ">Sovani 2008</a>). Whilst trials that have investigated doubling the dose of ICS early in exacerbations have been disappointing (<a href="./references#CD009019-bbs2-0031" title="FitzGeraldJM , BeckerA , SearsMR , MinkS , ChungK , LeeJ . Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax2004;59(7):550‐6. ">FitzGerald 2004</a>; <a href="./references#CD009019-bbs2-0034" title="HarrisonT , OborneJ , NewtonS , TattersfieldA . Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet2004;363(9405):271‐5. ">Harrison 2004</a>), with SiT it is possible for the patient to automatically increase both LABA and ICS when asthma worsens and to cut down again as symptoms improve. This holds out the prospect of maintaining control of asthma and preventing exacerbations with lower overall exposure to ICS. </p> <p>Concomitant delivery of ICS and LABA avoids the inadvertent use of LABA without prescribed ICS treatment, and although this method has been advocated as a new approach to asthma care (<a href="./references#CD009019-bbs2-0019" title="BarnesPJ . Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control. British Medical Journal2007;335(7618):513. ">Barnes 2007</a>), some have pointed out limitations in the current research evidence in children and adults with less severe asthma (<a href="./references#CD009019-bbs2-0021" title="BisgaardH . Effect of long‐acting Beta2 agonists on exacerbation rates of asthma in children. Pediatric Pulmonology2003;36(5):391‐8. ">Bisgaard 2003</a>; <a href="./references#CD009019-bbs2-0038" title="LipworthBJ , JacksonC . A SMART choice for primary care asthma therapy?. http://www.bmj.com/cgi/eletters/335/7618/513#178078 (accessed 13 October 2007). ">Lipworth 2007</a>). </p> <p>Fixed‐dose budesonide and formoterol against maintenance treatment with salmeterol and fluticasone has already been reviewed (<a href="./references#CD009019-bbs2-0037" title="LassersonTJ , FerraraG , CasaliL . Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2011, Issue 12. [DOI: 10.1002/14651858.CD004106.pub4] ">Lasserson 2011</a>). Previous reviews have also assessed budesonide/formoterol as reliever therapy (with identical maintenance treatment) against other reliever therapy (<a href="./references#CD009019-bbs2-0025" title="CatesCJ , LassersonTJ . Combination formoterol and inhaled steroid versus beta2‐agonist as relief medication for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD007085.pub2] ">Cates 2009</a>), and SiT versus fixed‐dose maintenance ICS and current best practice (<a href="./references#CD009019-bbs2-0026" title="CatesCJ , LassersonTJ . Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007313.pub2] ">Cates 2009a</a>; <a href="./references#CD009019-bbs2-0027" title="Cates ChristopherJ , KarnerC . Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD007313.pub3; CD007313] ">Cates 2013</a>). </p> <p>This review has identified and summarised clinical trials that compare single‐inhaler therapy for maintenance and relief with budesonide/formoterol (SiT) against maintenance treatment with combination inhalers (either salmeterol/fluticasone or budesonide/formoterol) and a SABA as relief. As SiT can be prescribed at a lower dose than other ICS/LABA combination therapy because of the additional ICS being received as reliever therapy, we decided that combination inhalers at a higher steroid maintenance dose would provide the most useful comparison. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009019-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009019-sec-0023"></div> <p>To assess the efficacy and safety of budesonide/formoterol in a single inhaler (SiT) to be used for both maintenance and reliever therapy in asthma in comparison with maintenance treatment provided through combination inhalers with a higher maintenance steroid dose (either fluticasone/salmeterol or budesonide/formoterol), along with additional fast‐acting beta<sub>2</sub>‐agonists for relief of symptoms. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009019-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009019-sec-0024"></div> <section id="CD009019-sec-0025"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009019-sec-0026"> <h4 class="title">Types of studies</h4> <p>We included randomised trials of parallel‐group design of at least 12 weeks' duration.</p> </section> <section id="CD009019-sec-0027"> <h4 class="title">Types of participants</h4> <p>Adults and children with a diagnosis of chronic asthma. We accepted study‐defined asthma and recorded the definition of asthma used in the studies. We did not include studies conducted in an ER setting. </p> </section> <section id="CD009019-sec-0028"> <h4 class="title">Types of interventions</h4> <section id="CD009019-sec-0029"> <h5 class="title">Eligible treatment group intervention</h5> <p>Any dose of combined budesonide and formoterol delivered through a single inhaler for maintenance and reliever therapy (SiT). </p> </section> <section id="CD009019-sec-0030"> <h5 class="title">Eligible control group treatment</h5> <p>Combination ICS/LABA inhalers (fluticasone/salmeterol or budesonide/formoterol) at a higher maintenance steroid dose than the maintenance dose in the SiT group, with additional fast‐acting beta<sub>2</sub>‐agonist inhaler for symptom relief. </p> </section> </section> <section id="CD009019-sec-0031"> <h4 class="title">Types of outcome measures</h4> <section id="CD009019-sec-0032"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009019-list-0001"> <li> <p>Exacerbations requiring hospitalisation.</p> </li> <li> <p>Exacerbations requiring oral corticosteroids.</p> </li> <li> <p>Serious adverse events (including mortality and life‐threatening events).</p> </li> </ol> </p> </section> <section id="CD009019-sec-0033"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009019-list-0002"> <li> <p>Severe exacerbations (composite outcome of hospitalisation/ER visit).</p> </li> <li> <p>Diary card morning and evening peak expiratory flow (PEF, L/min).</p> </li> <li> <p>Clinic spirometry (FEV<sub>1</sub>, mL). </p> </li> <li> <p>Number of rescue medication puffs required per day.</p> </li> <li> <p>Days with symptoms/symptom‐free days (%).</p> </li> <li> <p>Nocturnal awakenings (%).</p> </li> <li> <p>Quality of life.</p> </li> </ol> </p> </section> </section> </section> <section id="CD009019-sec-0034"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009019-sec-0035"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and from handsearching of respiratory journals and meeting abstracts (please see <a href="./appendices#CD009019-sec-0094">Appendix 1</a> for further details). All records in the CAGR coded as 'asthma' were searched using the following terms: </p> <p>("single inhaler" or SiT or SMART or relie* or "as need*" or as‐need* or prn or flexible or titrat*) and ((combin* or symbicort or viani) or ((budesonide or BUD) AND (formoterol or eformoterol))) </p> <p>We also conducted a search of ClinicalTrials.gov. The search terms are given in <a href="./appendices#CD009019-sec-0100">Appendix 2</a>. All databases were searched from their inception to November 2013, with no restriction on language of publication. </p> </section> <section id="CD009019-sec-0036"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and review articles for additional references. We searched the manufacturer's website (AstraZeneca clinical trials database) for additional study information for studies identified through the electronic searches. </p> </section> </section> <section id="CD009019-sec-0037"> <h3 class="title" id="CD009019-sec-0037">Data collection and analysis</h3> <section id="CD009019-sec-0038"> <h4 class="title">Selection of studies</h4> <p>After electronic literature searches were completed, two review authors independently selected articles on the basis of titles and abstracts for full‐text scrutiny. The review authors agreed on a list of articles, which were retrieved, and we subsequently assessed each study to determine whether it was a secondary publication of a primary study publication and whether the study met the entry criteria of the review. </p> </section> <section id="CD009019-sec-0039"> <h4 class="title">Data extraction and management</h4> <p>We recorded the definition of asthma used in the studies, as well as the entry criteria. We recorded whether asthma was defined according to guidelines. We summarised baseline severity of the condition (according to international guidelines, e.g. <a href="http://archie.cochrane.org/sections/documents/view?version=20525775881671575631120905150036%26format=REVMAN#REF-GINA-2011" target="_blank">GINA 2011</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=20525775881671575631120905150036%26format=REVMAN#REF-BTS_x002f_SIGN-2012" target="_blank">BTS/SIGN 2012</a>), persistence of symptoms and lung function among the enrolled participants, as well as data on prestudy maintenance therapies. </p> <p>We extracted the following characteristics.</p> <p> <ol id="CD009019-list-0003"> <li> <p>Design (description of randomisation, blinding, number of study centres and locations, number of study withdrawals). </p> </li> <li> <p>Participants (N, mean age, age range of the study, baseline lung function, % on maintenance ICS or ICS/LABA combination and average daily dose of steroid (inhaled beclomethasone (BDP) equivalent), entry criteria). </p> </li> <li> <p>Intervention (type and dose of component ICS and LABA, control limb dosing schedule, intervention limb dose adjustment schedule, inhaler device, study duration and run‐in). </p> </li> <li> <p>Outcomes (type of outcome analysis, outcomes analysed).</p> </li> </ol> </p> </section> <section id="CD009019-sec-0040"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias according to recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009019-bbs2-0036" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration. www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>) for the following items. </p> <p> <ol id="CD009019-list-0004"> <li> <p>Sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and investigators.</p> </li> <li> <p>Blinding of outcome assessors.</p> </li> <li> <p>Loss to follow‐up.</p> </li> <li> <p>Reporting bias.</p> </li> </ol> </p> <p>Each potential source of bias was graded as low, high or unclear risk of bias. We also noted other sources of bias. </p> </section> <section id="CD009019-sec-0041"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios, and continuous data as mean differences or standardised mean differences. </p> <p>Data for each of the outcomes considered by the review were extracted from the trial publication(s) or from correspondence with study authors or the manufacturer. Exacerbations, the primary outcome for this review, have been reported by subtype (hospitalisations, ER visits and courses of oral steroids) and as a composite outcome when the breakdowns were not given. Serious adverse events were considered together as fatal and non‐fatal events. </p> </section> <section id="CD009019-sec-0042"> <h4 class="title">Unit of analysis issues</h4> <p>We used participants (rather than events) as the unit of analysis. Some participants suffer more than one exacerbation over the course of a study, and these events are not independent. </p> </section> <section id="CD009019-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>The proportion of randomly assigned participants who provided data for the main outcomes has been reported and compared with the number of participants with events in each outcome category. </p> </section> <section id="CD009019-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>Statistical variation between combined studies was measured by the I<sup>2</sup> statistic (<a href="./references#CD009019-bbs2-0035" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. British Medical Journal2003;327:557‐60. ">Higgins 2003</a>). When this exceeded 20%, we investigated the possible causes of heterogeneity. </p> </section> <section id="CD009019-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to inspect funnel plots to see whether publication bias was evident if more than 10 studies had been included. When trial protocols had been published in advance, we compared the outcomes suggested in the trial protocol versus those reported for each trial. </p> </section> <section id="CD009019-sec-0046"> <h4 class="title">Data synthesis</h4> <p>Data were combined in <a href="./references#CD009019-bbs2-0041" title="The Nordic Cochrane Centre; Cochrane Collaboration. Review Manager (RevMan) Version 5. Copenhagen: The Nordic Cochrane Centre; Cochrane Collaboration, 2008. ">Review Manager 5</a>, using a fixed‐effect mean difference (calculated as a weighted mean difference) for continuous data variables, and a fixed‐effect odds ratio for dichotomous variables. For the primary outcomes of exacerbations and serious adverse events, we have calculated absolute effects for the different levels of risk, as represented by control group event rates over a specified time period using the pooled odds ratio and its confidence interval and an online calculator (<a href="http://www.nntonline.net/VisualRx" target="_blank">Visual Rx</a>). </p> <p>A Summary of findings table was constructed for the primary outcomes.</p> </section> <section id="CD009019-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We analysed studies that compared SiT with salmeterol/fluticasone together with those studies that compared SiT with maintenance budesonide/formoterol, and we presented both the results of each comparison group separately and the pooled result. In the case of <a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a>, which had two intervention groups relevant to this review, we halved the number of participants in the group that served twice as the control to avoid overrepresentation. For dichotomous outcomes, we halved both the numerator and the denominator of the group that served twice, and for continuous outcomes, we halved only the number of participants. It is noted that this may have affected the power of the subgroup analyses and tests for subgroup differences, and this was considered in their interpretation. </p> <p>If the search had returned data on both adult and child populations, we planned to pool the data in subgroups. Adult studies were considered as those that recruited participants from age 18 upwards, and adult and adolescent studies were considered as those that recruited participants from age 12 upwards. We considered participants in studies in which the upper age limit was 12 years as children, and in studies where the upper age limit was 18 years as children and adolescents. We aimed to perform subgroup analyses in relation to asthma severity (classified according to major international guidelines (<a href="./references#CD009019-bbs2-0022" title="British Thoracic Society/ Scottish Intercolleate Guideline Network. British Guidelines on the Management of Asthma [revised January 2012]. http://www.sign.ac.uk/ (accessed 5 September 2012). ">BTS/SIGN 2012</a>; <a href="./references#CD009019-bbs2-0032" title="GINA . Global strategy for asthma management and prevention. http://www.ginasthma.org/ (accessed 10 March 2013). ">GINA 2012</a>) and dose equivalence of treatments used) but found that it was more appropriate to remove one study in a sensitivity analysis (see <i>Outcomes and analysis structure</i> in <a href="./full#CD009019-sec-0049">Results</a>). </p> </section> <section id="CD009019-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analysis has been conducted on the basis of risk of bias in studies and baseline severity (based on baseline use of ICS and baseline percentage predicted FEV<sub>1</sub>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009019-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009019-sec-0049"></div> <section id="CD009019-sec-0050"> <h3 class="title">Description of studies</h3> <p>Full details of the conduct and characteristics of each included study can be found in <a href="./references#CD009019-sec-0109" title="">Characteristics of included studies</a>, and reasons for exclusion when full texts had to be viewed are given in <a href="./references#CD009019-sec-0110" title="">Characteristics of excluded studies</a>. </p> <section id="CD009019-sec-0051"> <h4 class="title">Results of the search</h4> <p>Three‐hundred fifty‐five references were identified through database searching and through additional searching of industry databases and relevant reference lists. Of these, 241 were excluded upon a sift of the titles and abstracts. One hundred six records were assessed for eligibility, of which 74 were found to not meet the review's inclusion criteria (reasons for exclusion can be found in <a href="#CD009019-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009019-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009019-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009019-sec-0052"> <h4 class="title">Included studies</h4> <p>Four studies (32 citations) met the inclusion criteria, randomly assigning 9130 people with a diagnosis of asthma to the comparisons of interest in this review. <a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a> contributed the largest sample size to the analyses, with 3335 people randomly assigned across three intervention groups. <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> included the smallest number of people, with 1343 participants randomly assigned to the two arms relevant to this review. </p> <section id="CD009019-sec-0053"> <h5 class="title">Design and duration</h5> <p>All studies were multi‐centre, randomised, parallel‐group controlled trials, taking place at between 22 and 235 centres. Two were six‐month double‐blind studies (<a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a>; <a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a>), and two administered the medications on an open‐label basis for one year (<a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a>; <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a>). Three studies described two‐week run‐in phases, during which participants received their usual ICS therapy (and LABA when this was part of their treatment regimen), with terbutaline as rescue medication. <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> did not describe a run‐in period. </p> </section> <section id="CD009019-sec-0054"> <h5 class="title">Participant inclusion and exclusion criteria</h5> <p>Full details of the inclusion and exclusion criteria of each trial can be found in <a href="./references#CD009019-sec-0109" title="">Characteristics of included studies</a>. Inclusion and exclusion criteria were very similar across trials. All trials included outpatients at least 12 years of age and thus were treated as adult and adolescent studies. All participants were required to have a diagnosis of persistent asthma characterised by at least one exacerbation in the 12 months before study entry. In two trials, participants' prebronchodilator FEV<sub>1</sub> had to be greater than 50% predicted normal: One required between 40% and 90% (<a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a>), and the other trial did not specify (<a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a>). All trials recruited participants taking regular ICS therapy and in regular need of a rescue inhaler. Studies excluded participants who had recently had a respiratory infection or had recently received a course of systemic corticosteroids. Two trials stated that participants with a smoking history of greater than 10 pack‐years were excluded (<a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a>; <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a>). Two trials excluded participants who had been taking an ICS/LABA inhaler during the previous three (<a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a>) or 12 months (<a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a>). </p> <p><i>Baseline characteristics of participants</i> </p> <p>Full details of the baseline characteristics of participants in each study can be found in <a href="./references#CD009019-sec-0109" title="">Characteristics of included studies</a>, and a summary in <a href="#CD009019-tbl-0002">Table 1</a>. Participants' mean age was similar across the trials, ranging from 38 to 45 years. Trials generally included more women than men (between 38% and 44% male). Participants' mean FEV<sub>1</sub> percentage predicted was between 70% and 73% in three of the trials and was significantly higher in <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a>, at 96%. The mean daily dose of steroid being taken at baseline (BDP equivalent) ranged from 636 to 888 μg for individual arms within the studies. </p> <div class="table" id="CD009019-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Age range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> % Male</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> FEV<sub>1</sub> % predicted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean baseline daily ICS (BDP)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) SiT</p> <p>2) Flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 (range 45 to 144)</p> <p>71 (range 45 to 222)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>705 (range 250 to 1600)</p> <p>720 (range 200 to 2000)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) SiT</p> <p>2) Flut/salm</p> <p>3) Bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (SD 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>43</p> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> <p>73</p> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>740 (SD 240)</p> <p>744 (SD 230)</p> <p>750 (SD 262)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) SiT</p> <p>2) Bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (SD 19)</p> <p>45 (SD 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐87</p> <p>12‐95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95 (SD 18)</p> <p>97 (SD 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>636 (SD 293)</p> <p>650 (SD 315)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) SiT</p> <p>2) Flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐80</p> <p>12‐84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73 (range 39 to 115)</p> <p>73 (range 28 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888 (range 500 to 2000)</p> <p>881 (range 400 to 3000)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Where only one line of data appears in a cell, data were not available for individual trial arms but rather for the whole study<br/> population. </p> </div> </div> </section> <section id="CD009019-sec-0055"> <h5 class="title">Characteristics of the interventions</h5> <p><a href="#CD009019-tbl-0003">Table 2</a> shows the planned daily treatment schedules and total ICS received with SiT and with the comparison interventions in each of the four studies. <a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a> and <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> used a daily SiT dose of 320/9 μg, and <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> also allowed the lower dose of 160/9 to be given, depending on baseline ICS use. <a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a> and <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a> used the higher SiT dose of 640/18 μg per day. All studies used 160/4.5‐μg inhalations as the reliever dose in SiT. Three studies used fluticasone/salmeterol in the comparison group—two at a daily dose of 500/100 μg (ICS/LABA) (<a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a>; <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a>), and the third at 1000/100 (<a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a>). Two studies used budesonide/formoterol in the control group—<a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a> at a dose of 640/18 μg, and <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> at 320/18 μg or 640/18 μg, depending on baseline ICS dose. Three of the studies used terbutaline as the SABA in the control group, and <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a> used salbutamol. Although some variation between studies was noted, the planned and total received ICS doses (presented as BDP equivalents) were consistently lower in SiT. </p> <div class="table" id="CD009019-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of the interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b> Study ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> Single‐inhaler therapy (budesonide/formoterol)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> Comparison ICS/LABA total planned daily dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>Planned daily maintenance schedule</i> <br/> (with reliever dose)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>Total ICS received per</i> <br/> <i>day (mean, BDP</i> μ<i>g)</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>Planned daily maintenance schedule</i> <br/> (with reliever)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>Total ICS received per</i> <br/> <i>day (mean, BDP</i> μ<i>g)</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640/18 μg<br/> (160/4.5 as needed) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flut/salm 1000/100 μg<br/> (terbutaline) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>320/9 μg<br/> (160/4.5 as needed) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flut/salm 500/100 μg<br/> (terbutaline) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bud/form 640/18 μg<br/> (terbutaline) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320/9 or 160/9 μg based on previous ICS use</p> <p>(160/4.5 or 80/4.5 as needed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bud/form 640/18 or 320/18 μg<br/> (terbutaline) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>574</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640/18 μg<br/> (160/4.5 as needed) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flut/salm 500/100 μg<br/> (salbutamol) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1166</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD009019-sec-0056"> <h5 class="title">Outcomes and analysis structure</h5> <p>All but one of the studies reported the number of people with exacerbations requiring hospitalisation or an ER visit, but these data could not be used for the primary hospitalisation outcome, as there was no way of knowing how many people had experienced hospitalisation and how many had been to the ER (or both). AstraZeneca, the drug company that funded all of the included studies, was unable to provide data for hospitalisations alone, so no data could be analysed for this primary outcome. All studies reported serious adverse events that could be meta‐analysed. Exacerbations and adverse events were coded by study investigators, who were aware of allocation in <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> and <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a>. Studies did not routinely report as a separate outcome the number of people requiring a course of oral steroids , but these data were sought from the pharmaceutical company sponsoring the studies and owning the data (AstraZeneca) and are presented in <a href="./references#CD009019-fig-0005" title="">Analysis 1.1</a>. The data for hospitalisations and ER visits combined are reported under the heading 'Severe exacerbations' in <a href="./references#CD009019-fig-0007" title="">Analysis 1.3</a>. </p> <p>Secondary outcomes were generally poorly reported. Morning and evening PEF, symptom‐free days and nocturnal awakenings were reported by only two studies (<a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a>; <a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a>), representing three comparisons in each outcome. The same two studies also reported rescue medication use, and additional data were provided upon request by AstraZeneca for <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a>. Two studies reported predose FEV<sub>1</sub> (<a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a>; <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a>), and these data for <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> were provided by AstraZeneca. <a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a> and <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a> reported symptoms as measured by the Asthma Control Questionnnaire (ACQ)‐5, meaning that no data were available on the use of budesonide/formoterol by the control group. Only <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a> reported a measure of quality of life that could be analysed. </p> <p>Meta‐analyses compared SiT versus combination inhalers of a higher fixed maintenance dose and additional fast‐acting beta<sub>2</sub>‐agonists for relief. Results were subgrouped according to the ICS/LABA combination in the comparison group (i.e. fluticasone/salmeterol or budesonide/formoterol). </p> <p>Although we planned to carry out subgroup analyses according to symptom severity, we decided that a sensitivity analysis excluding <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> was more appropriate. Participants in <a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a>, <a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a> and <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a> had mean baseline lung function between 70% and 75% predicted and baseline ICS use towards the top of the medium range. Participants were generally also required to have used ICS/LABA for one to three months, to have had one or more exacerbations over the last year and to have the need for reliever medication on three to five days out of seven. Conversely, although participants in <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> had comparable mean baseline ICS doses of around 650 μg budesonide in both groups, percent predicted FEV<sub>1</sub> was much higher, at 95% and 97%,respectively. </p> </section> </section> <section id="CD009019-sec-0057"> <h4 class="title">Excluded studies</h4> <p>Reasons for study exclusion can be found in <a href="./references#CD009019-sec-0110" title="">Characteristics of excluded studies</a>, and associated references are provided in <a href="./references#CD009019-bbs1-0002" title="">Excluded studies</a>. Three studies (<a href="./references#CD009019-bbs2-0009" title="NCT00839800 . Study to Investigate the Efficacy of Symbicort SMART. (SAKURA). www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D589LC00001; clinicaltrials.gov study ID: NCT00839800] ">D589LC00001 2011 [SAKURA]</a>; <a href="./references#CD009019-bbs2-0014" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:A37 Poster J75. BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy &amp; Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.[see comment]. American Journal of Respiratory &amp; Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:A37 Poster J93. PistolesiM , GodardP , AlbersR , EkstromT . Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma [Abstract]. European Respiratory Journal2004;24 Suppl 48:509s. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">O'Byrne 2005 [STAY]</a>; <a href="./references#CD009019-bbs2-0015" title="AstraZenecaSD . Efficacy of Symbicort® Turbuhaler® 160/4.5 ìg as needed versus Oxis® 4.5 ìg as needed and Bricanyl® 0.4 mg as needed in adults and adolescents with asthma receiving Symbicort® Turbuhaler® 160/4.5 ìg twice daily as maintenance treatment. A 12‐month, randomised, double‐blind, parallel‐group, active‐controlled, phase IIIB, multi‐centre study. www.astrazenecaclinicaltrials.com/‎ (accessed 24 April 2012). PistolesiM , GodardP , AlbersR , EkstromT . Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma [Abstract]. European Respiratory Journal2004;24 Suppl 48:509s. RabeKF , AtienzaT , MagyarP , LarssonP , JorupC , LallooUG . Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double‐blind study.[see comment]. Lancet2006;368(9537):744‐53. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Rabe 2006 [SMILE]</a>) were excluded at a late stage, when it became clear that the maintenance ICS dose in the control group was not higher than the maintenance dose prescribed for the intervention group, and hence they did not meet the inclusion criteria. </p> </section> </section> <section id="CD009019-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>For details of the risk of bias rating for each study and the reasons for each rating, see <a href="./references#CD009019-sec-0109" title="">Characteristics of included studies</a>. A summary of the risk of bias judgements by study and domain (allocation generation, allocation concealment, blinding and incomplete data) can be found in <a href="#CD009019-fig-0002">Figure 2</a>. All studies were funded by only one pharmaceutical company (AstraZeneca) and were mostly free from methodological biases, although two studies were rated at high risk for blinding because the inhalers were delivered in an open‐label design. Evidence of selective outcome reporting was found in two of the trials, and this is reflected in the grade ratings of the affected outcomes. </p> <div class="figure" id="CD009019-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009019-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009019-sec-0059"> <h4 class="title">Allocation</h4> <p>It is unlikely that selection bias compromised the validity of this review. All studies used adequate methods to allocate participants to groups and were rated as low risk of bias for sequence generation. All studies stated that randomisation codes were sequentially assigned from a list that was computer generated, and this was confirmed through communication with AstraZeneca. <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> stated that allocation was stratified according to ICS dose at baseline, and <a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a> stated that randomisation occurred in balanced blocks. </p> <p>All studies used adequate methods to conceal the allocation sequence until assignment and were rated as low risk of bias in this domain. Three studies (<a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a>; <a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a>; <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a>) provided individual treatment codes in sealed envelopes, and one provided allocation by means of an interactive voice response system (<a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a>). </p> </section> <section id="CD009019-sec-0060"> <h4 class="title">Blinding</h4> <p>Ineffective blinding procedures may have introduced bias into the analyses in this review. Two studies used adequate double‐dummy procedures and labelling to conceal the medications from participants and providers and were rated as low risk of bias (<a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a>; <a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a>). The other two studies used an open‐label design and therefore were at high risk of performance and detection bias by participants and investigators (<a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a>; <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a>). </p> <p>Three studies did not state whether outcome assessors were blind to treatment allocation (<a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a>; <a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a>; <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a>), so were rated as unclear. The remaining study described dose titration by investigators, who appeared to be those who rated outcomes, and hence was rated at high risk of bias (<a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a>). </p> </section> <section id="CD009019-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>Little evidence of attrition bias was found in the included studies. Withdrawal rates were low (highest 14% in the fluticasone/salmeterol group of <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a>) and even between groups in all studies. </p> </section> <section id="CD009019-sec-0062"> <h4 class="title">Selective reporting</h4> <p>Varied evidence of reporting bias was found in the four included studies, and this may have affected the robustness of some analyses. <a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a> was rated as low risk of bias, as we were able to locate the trial registration and check it against the study report. Although it appeared that <a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a> reported all relevant outcomes, we could not locate the study protocol and hence could not confirm that all predefined outcomes were included in the published report. <a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> and <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a> were rated as high risk of bias because they omitted data or did not provide it in a reasonable format for one or more of the outcomes. Although additional outcome data and information about study methodology were provided by AstraZeneca, several outcomes still did not include data from all four studies. </p> </section> <section id="CD009019-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>No other sources of bias were identified.</p> </section> </section> <section id="CD009019-sec-0064"> <h3 class="title" id="CD009019-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD009019-tbl-0001"><b>Summary of findings for the main comparison</b> SiT for maintenance/relief compared with higher‐dose ICS/LABA + SABA for chronic asthma in adults and children</a> </p> <section id="CD009019-sec-0065"> <h4 class="title">Single‐inhaler therapy (SiT) versus ICS/LABA combination inhalers at a higher ICS dose with separate SABA relief </h4> <p>Full details of the analyses and their GRADE ratings can be found in <a href="./references#CD009019-sec-0092" title="">Data and analyses</a> and <a href="./full#CD009019-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD009019-sec-0066"> <h5 class="title">Primary outcomes</h5> <p>Subgroup analyses based on the ICS/LABA combination in the comparison group were performed for all of the primary outcomes. No evidence of subgroup differences was found for exacerbations requiring oral steroids or serious adverse events, although splitting the SiT group in <a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a> may have resulted in an underestimation of subgroup differences. For full details of the individual subgroup effects, see <a href="./references#CD009019-fig-0005" title="">Analysis 1.1</a> and <a href="./references#CD009019-fig-0006" title="">Analysis 1.2</a>. Although two of the studies were open‐label, one of which recruited a less severe population, we chose not to downgrade the evidence for these reasons based on the sensitivity analyses presented. </p> <section id="CD009019-sec-0067"> <h6 class="title">Exacerbations requiring hospitalisation</h6> <p>All but one of the studies reported the number of people with exacerbations requiring hospitalisation <i>or</i> an ER visit, but these data could not be used, as there was no way of knowing how many people had been admitted to hospital for an exacerbation and how many had been to the ER. AstraZeneca, the drug company that funded all of the included studies, was unable to provide data related purely to hospitalisations. Available data (composite of exacerbations requiring hospitalisation or an ER visit) are shown in the secondary outcome labelled 'Severe exacerbations'. </p> </section> <section id="CD009019-sec-0068"> <h6 class="title">Exacerbations requiring a course of oral corticosteroids</h6> <p>SiT reduced the number of people who had an exacerbation requiring a course of oral corticosteroids (odds ratio (OR) 0.75, 95% confidence interval (CI) 0.65 to 0.87; I<sup>2</sup> = 0%, P = 0.82). AstraZeneca provided data for 9096 people across all four studies, and the evidence was rated as high quality (no serious imprecision, inconsistency, risk of bias or indirectness). <a href="#CD009019-fig-0003">Figure 3</a> shows the absolute effect in a Cates plot. </p> <div class="figure" id="CD009019-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Cates plot: In the control group, 10 of 100 people had an exacerbation requiring oral steroids over eight months compared with eight (95% CI seven to nine) of 100 in the SiT group." data-id="CD009019-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Cates plot: In the control group, 10 of 100 people had an exacerbation requiring oral steroids over eight months compared with eight (95% CI seven to nine) of 100 in the SiT group. </p> </div> </div> </div> </section> <section id="CD009019-sec-0069"> <h6 class="title">Number of people with serious adverse events (including mortality)</h6> <p>We could not rule out a possible increase or decrease in serious adverse events with SiT (OR 0.92, 95% CI 0.74 to 1.13; I² = 0%, P = 0.98), based on 9130 participants from all four trials, and no statistical heterogeneity was observed between study results. The evidence was downgraded once for imprecision and was rated as moderate quality, as the confidence intervals were wide. </p> <section id="CD009019-sec-0070"> <p><b>Sensitivity analysis—baseline severity</b></p> <p><a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> was removed from the three primary outcomes in a sensitivity analysis because the population had much higher baseline percentage predicted FEV<sub>1</sub> than that in the other studies. The study did not report exacerbations requiring hospitalisation, so this outcome was not affected. Conclusions for exacerbations requiring oral steroids (<a href="./references#CD009019-fig-0005" title="">Analysis 1.1</a>; <a href="./references#CD009019-fig-0016" title="">Analysis 2.1</a>) and serious adverse events (<a href="./references#CD009019-fig-0006" title="">Analysis 1.2</a>; <a href="./references#CD009019-fig-0017" title="">Analysis 2.2</a>) were unaffected by removing the study. </p> </section> <section id="CD009019-sec-0071"> <p><b>Sensitivity analysis—blinding</b></p> <p><a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> and <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a> were removed from the primary analyses for a sensitivity analysis on the basis of performance and detection bias (<a href="#CD009019-fig-0002">Figure 2</a>). Results were very similar with and without the studies for exacerbations requiring oral steroids (<a href="./references#CD009019-fig-0005" title="">Analysis 1.1</a>; <a href="./references#CD009019-fig-0019" title="">Analysis 3.1</a>), serious adverse events (<a href="./references#CD009019-fig-0006" title="">Analysis 1.2</a>; <a href="./references#CD009019-fig-0020" title="">Analysis 3.2</a>) and exacerbations requiring hospitalisation or an ER visit (<a href="./references#CD009019-fig-0018" title="">Analysis 2.3</a>; <a href="./references#CD009019-fig-0021" title="">Analysis 3.3</a>), </p> </section> </section> </section> <section id="CD009019-sec-0072"> <h5 class="title">Secondary outcomes</h5> <p>Subgroup analyses based on the ICS/LABA combination in the comparison group were performed for all of the secondary outcomes. In all cases, no heterogeneity (I² = 0%) between subgroups was noted, so only the pooled effect is reported to increase precision. Individual subgroup effects for each outcome can be found in <a href="./references#CD009019-sec-0092" title="">Data and analyses</a>. </p> <section id="CD009019-sec-0073"> <h6 class="title">Severe exacerbations (those requiring hospitalisation or an ER visit)</h6> <p>The number of people who had at least one exacerbation meeting these criteria was lower in the SiT group (OR 0.72, 95% CI 0.57 to 0.90; I<sup>2</sup> = 0%, P = 0.66), based on 7768 participants from three of the studies. No heterogeneity was observed, and the evidence was rated as high quality. <a href="#CD009019-fig-0004">Figure 4</a> shows the absolute effect in a Cates plot. </p> <div class="figure" id="CD009019-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Cates plot: In the control group, five of 100 people had an exacerbation requiring hospitalisation or an ER visit over eight months, compared with four (95% CI three to five) of 100 in the SiT group." data-id="CD009019-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Cates plot: In the control group, five of 100 people had an exacerbation requiring hospitalisation or an ER visit over eight months, compared with four (95% CI three to five) of 100 in the SiT group. </p> </div> </div> </div> </section> <section id="CD009019-sec-0074"> <h6 class="title">Morning peak expiratory flow (PEF, L/min)</h6> <p>SiT was not significantly different from higher‐dose ICS/LABA for morning PEF (mean difference (MD) ‐1.46, 95% CI ‐3.85 to 0.94; I² = 0%, P = 0.67), based on 5624 participants in two studies (three comparisons). No heterogeneity was observed between studies, and imprecision was judged to be not severe enough to warrant downgrading. However, given that two studies could not be included in the analysis, the outcome was downgraded for publication bias. The quality of this evidence was therefore rated as moderate. </p> </section> <section id="CD009019-sec-0075"> <h6 class="title">Evening peak expiratory flow (PEF, L/min)</h6> <p>No significant difference between SiT and the control intervention was seen for evening PEF, and the magnitude of the mean difference was smaller (MD 0.11, 95% CI ‐2.24 to 2.46; I² = 0%, P = 0.61). Again, this was based on 5624 participants in two trials, and no heterogeneity was noted between studies. The quality of evidence was rated as moderate for the same reasons as in the morning PEF analysis. </p> </section> <section id="CD009019-sec-0076"> <h6 class="title">Predose forced expiratory volume in one second (FEV<sub>1</sub>, mL) </h6> <p>SiT was associated with slightly better predose FEV<sub>1</sub> compared with the control intervention (MD 19.35, 95% CI 2.72 to 35.98; I² = 0%, P = 0.65) with no heterogeneity. The analysis was based on 7566 participants in three trials (representing four comparisons), and the evidence was rated as moderate quality, as downgraded for imprecision because the confidence intervals included almost no benefit. </p> </section> <section id="CD009019-sec-0077"> <h6 class="title">Rescue medication puffs required per day</h6> <p>Because of the nature of the comparison, rescue medication referred to different treatments in the intervention and control arms: In the SiT group, rescue medication is the number of additional puffs of budesonide/formoterol combination inhaler taken per day, and in the control arm, it is the number of puffs of the SABA inhaler provided as reliever medication. In each case, it captures the need for additional medication on top of regular twice‐daily maintenance treatment. </p> <p>The need for rescue mediation was not statistically different between SiT and controls (MD ‐0.09, 95% CI ‐0.27 to 0.09; I² = 93%, P &gt; 0.00001), based on 7725 participants in three trials (representing four comparisons), but considerable heterogeneity was observed between the two studies. As such, a random‐effects model was used, and the outcome was downgraded for inconsistency. The outcome was also downgraded for imprecision, and the evidence was rated as low quality. </p> </section> <section id="CD009019-sec-0078"> <h6 class="title">Symptoms rating—Asthma Control Questionnaire (ACQ‐5)</h6> <p>Moderate‐quality evidence suggested a small but significant improvement with SiT on the ACQ‐5 (MD ‐0.04, 95% CI ‐0.07 to 0.00; I² = 3%, P = 0.31), based on 4432 participants in two studies, and very little heterogeneity was noted between studies. Both studies used fluticasone/salmeterol in the control intervention. The evidence was downgraded for publication bias, as two studies (representing three comparisons) did not report the outcome. </p> </section> <section id="CD009019-sec-0079"> <h6 class="title">Symptom‐free days (%)</h6> <p>SiT was not significantly different from higher‐dose combination therapy in terms of symptom‐free days (MD ‐1.16, 95% CI ‐2.99 to 0.68; I² = 0%, P = 0.66), based on 5644 participants in two trials (representing three comparisons), and no heterogeneity was seen between the studies. The evidence was downgraded for publication bias only and was rated as moderate quality. </p> </section> <section id="CD009019-sec-0080"> <h6 class="title">Nocturnal awakenings (%)</h6> <p>Nocturnal awakenings were reduced with SiT (MD ‐1.08, 95% CI ‐2.13 to ‐0.03; I² = 0%, P = 0.92), based on 5624 participants in two studies (in three comparisons). No heterogeneity was observed between the studies, although again, two studies were missing from the analysis. As such, the outcome was downgraded for publication bias and was rated as moderate quality. </p> </section> <section id="CD009019-sec-0081"> <h6 class="title">Quality of life—Asthma Quality of Life Questinnaire (AQLQ)</h6> <p>Evidence of very low quality suggested a small benefit of SiT compared with a higher‐dose fluticasone/salmeterol combination (MD ‐0.06, 95% CI ‐0.10 to ‐0.02). This was based on one study with 2143 participants (<a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a>). The outcome was downgraded for the methodological risk of bias in <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a>. As none of the other three studies reported a quality of life measure that could be included in the meta‐analysis, the evidence was downgraded twice for publication bias. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009019-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009019-sec-0082"></div> <section id="CD009019-sec-0083"> <h3 class="title" id="CD009019-sec-0083">Summary of main results</h3> <p>Four studies were included, randomly assigning 9130 participants with a diagnosis of persistent/chronic asthma (Step three and above; <a href="./references#CD009019-bbs2-0032" title="GINA . Global strategy for asthma management and prevention. http://www.ginasthma.org/ (accessed 10 March 2013). ">GINA 2012</a>) to the comparisons of interest in this review. None of the studies included children younger than age 12, so we were unable to draw conclusions for this group of participants. </p> <p>Meta‐analyses compared SiT versus combination inhalers at a higher dose alongside fast‐acting beta<sub>2</sub>‐agonists for relief. Results were subgrouped according to the ICS/LABA combination used in the comparison group (i.e. fluticasone/salmeterol or budesonide/formoterol), but because no significant differences were noted for the primary outcomes, we have summarised the pooled estimates. Trials included more women than men, with mean age ranging from 38 to 45 and mean baseline steroid dose (BDP equivalent) from 636 to 888 μg. Mean baseline FEV<sub>1</sub> percentage predicted was between 70% and 73% in three of the trials, and 96% in another. </p> <p>Fewer people taking SiT had an exacerbation requiring a course of oral steroids (OR 0.75, 95% CI 0.65 to 0.87) or requiring hospitalisation or a visit to the ER (OR 0.72, 95% CI 0.57 to 0.90). Data for hospitalisations independent from the other exacerbation criteria were not available. We could not rule out the possibility of SiT increasing or decreasing serious adverse events (OR 0.92, 95% CI 0.74 to 1.13). No important variation was seen in the main findings, and they were mostly rated high quality (i.e. further research is very unlikely to change our confidence in the estimate of effect). </p> <p>Inconsistent reporting of secondary outcomes reduced our confidence in these findings. No significant difference was observed between SiT and higher‐dose combinations for morning PEF, evening PEF, rescue medication use or number of symptom‐free days. On three secondary outcomes for which SiT showed a statistically significant benefit, the magnitude of effect was not deemed clinically meaningful (FEV<sub>1</sub>, nocturnal awakenings and quality of life). </p> <p>Sensitivity analyses to explore two potential moderators of effect (baseline severity and blinding) did not change conclusions, but differences in dose regimens and in participant characteristics are likely to have introduced some inconsistency in the findings. In addition, although all studies were funded by AstraZeneca, which provided additional data for several outcomes, methodological differences such as blinding and inclusion criteria may reduce our confidence in the results. </p> </section> <section id="CD009019-sec-0084"> <h3 class="title" id="CD009019-sec-0084">Overall completeness and applicability of evidence</h3> <p>None of the studies included participants younger than age 12, so the evidence can be applied only to adults and adolescents. Single‐inhaler therapy is not currently licenced for children younger than age 18, and the only study that included children did not meet the inclusion criteria for this review (<a href="./references#CD009019-bbs2-0014" title="BatemanED , PalmqvistM , JuniperEF , ZhuY , EkstromT . Single inhaler therapy with budesonide/formoterol has superior efficacy to fixed‐dose budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:A37 Poster J75. BisgaardH , HultquistC . Budesonide/formoterol for maintenance and as needed ‐ a new approach to asthma management in children [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 1060. BisgaardH , LeRouxP , BjamerD , DymekA , VermeulenJH , HultquistC . Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest2006;130(6):1733‐43. BruceSA , SchererYK . Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence‐Based Nursing2005;8(3):78. O'ByrnePM . Acute asthma intervention: Insights from the STAY study. Journal of Allergy &amp; Clinical Immunology2007;119(6):1332‐6. O'ByrnePM , BisgaardH , GodardPP , PistolesiM , PalmqvistM , ZhuY , et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.[see comment]. American Journal of Respiratory &amp; Critical Care Medicine2005;171(2):129‐36. O'ByrnePM , GodardP , PistolesiM , EkstromT . Single inhaler therapy with budesonide/formoterol improves asthma control compared with fixed dosing with budesonide/formoterol or a higher dose of budesonide alone [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:A37 Poster J93. PistolesiM , GodardP , AlbersR , EkstromT . Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma [Abstract]. European Respiratory Journal2004;24 Suppl 48:509s. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">O'Byrne 2005 [STAY]</a>). In addition, no data were available for one of the primary outcomes—exacerbations leading to hospitalisation—representing an important gap in the evidence. Although exacerbations were reported in several other ways, hospitalisation is distinct from the other classifications because of the extent of associated healthcare costs and disruption for the participant. </p> <p>Participants in <a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a>, <a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a> and <a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a> had mean baseline lung function between 70% and 75% predicted and baseline ICS use towards the top of the medium range. Participants in these studies generally were required to have used LABA/ICS for one to three months, to have had one or more exacerbations in the past year and to have needed reliever medication on at least three days a week. On the basis of the sensitivity analysis to investigate changes in primary outcomes after exclusion of the one remaining study (<a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a>) recruiting a less severe population, it seems likely that the results of this review are applicable to patients of somewhat different severities.<br/> <br/> A degree of variation between studies was seen in the amount of ICS received, and this may be an important source of heterogeneity; in the SiT groups, the actual received steroid dose ranged from 454 to 1238 BDP equivalent, and from 574 to 2000 in the comparison groups. In the individual studies, people in the comparison group always received more ICS than those in the SiT group (using the amount of ICS from the maintenance SiT dose alone, or the amount from both maintenance and relief inhalations), but the absolute levels were highly variable among studies. The variability in doses may reflect the design of the studies and differences in baseline severity, although the sensitivity analysis excluding one study with very different inclusion criteria did not change the results. The dose differences might also reflect a certain variability in guidelines for the treatment of asthma associated with the fact that the studies were performed in different years and in different countries. For this reason, we were unable to draw conclusions about dose. </p> <p>A potential issue is the generalisability of the SiT approach and results to clinical practice: All studies were conducted in a controlled manner, with regular follow‐up and specific training in the use of inhalers, and this might be difficult to reproduce in the day‐by‐day clinical work of general practitioners and even specialists. Adherence to treatment is one of the main factors limiting clinical efficacy of interventions in asthma; this is recognised and addressed in current guidelines (<a href="./references#CD009019-bbs2-0022" title="British Thoracic Society/ Scottish Intercolleate Guideline Network. British Guidelines on the Management of Asthma [revised January 2012]. http://www.sign.ac.uk/ (accessed 5 September 2012). ">BTS/SIGN 2012</a>; <a href="./references#CD009019-bbs2-0032" title="GINA . Global strategy for asthma management and prevention. http://www.ginasthma.org/ (accessed 10 March 2013). ">GINA 2012</a>). </p> <p>Another potential issue regards patients who tend to overuse their relief medications and whether the intensive instruction and management of participants in trials are representative of clinical practice. Overuse of inhalers is certainly something to consider in the clinical management of all patients with asthma, regardless of the type of device or beta<sub>2</sub>‐agonist prescribed as relief, but this is something that occurs relatively seldom nowadays, especially in patients reaching good control of their symptoms with the addition of inhaled steroids. An associated concern is the potential for overconsumption of inhaled steroids associated with single‐inhaler therapy. However, the current meta‐analysis shows in a good sample size that participants treated in the SiT arm had in fact received lower doses of inhaled steroids during and at the end of the trials, and this was associated with a reduced need for systemic steroids. The review did not look at specific adverse events related to steroid use to limit the number of outcomes; instead the review authors looked generally at the rate of more serious events. Analysing the data in this way could have masked potential differences in the rates of overall adverse events of any severity or of particular adverse events associated with ICS use. </p> <p>In the light of the raised safety concerns associated with ICS+LABA therapy, critical evaluation of safety outcomes becomes very important. The title included evaluation of the safety of the combination; however, certain important issues including withdrawal overall and withdrawal due to specific reasons, adverse effects overall and specific adverse effects have not been addressed in the review. It would be great to address the issues of withdrawal as an indirect support for the primary outcome. </p> </section> <section id="CD009019-sec-0085"> <h3 class="title" id="CD009019-sec-0085">Quality of the evidence</h3> <p>Some of the results may be subject to detection and performance bias because two of the studies did not blind study medication from participants and investigators. Of these two studies, it was clear that in one, outcome assessors were also unblinded, and in the other, insufficient information was provided for review authors to judge. Similarly, use of different inhalers and techniques for the intervention and control arms in some ways precluded true blinding, and inhaler type may have introduced heterogeneity into some of the outcomes. </p> <p>In addition, several of the secondary outcomes contain only one or two studies; this prevented any strong conclusions from being drawn, despite the fact that AstraZeneca provided additional data for several of the outcomes. As only four included studies were identified, missing data from even one study could have a serious affect on the analysis. For this reason, unless all four studies could be included in the analysis, the evidence was downgraded for publication bias and was rated as moderate quality at best. We did not contact individual authors for extra data but liaised directly with AstraZeneca to make every effort to include all studies in as many of the outcomes as possible. </p> </section> <section id="CD009019-sec-0086"> <h3 class="title" id="CD009019-sec-0086">Potential biases in the review process</h3> <p>We are confident that all identifiable studies were found by using additional methods to catch anything that might not have been found in the main electronic search (e.g. searching drug company databases and clinical trial registration sites, checking reference lists). However, although every effort was made to find and include unpublished data, unpublished studies (industry funded or otherwise) may exist that might change our confidence in the conclusions (<a href="./references#CD009019-bbs2-0042" title="SongF , ParekhS , HooperL , LokeY , RyderJ , SuttonA , et al. Dissemination and publication of research findings: an updated review of related biases. http://www.google.co.uk/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;ved=0CDYQFjAA&amp;url=http%3A%2F%2Fwww.hta.ac.uk%2Ffullmono%2Fmon1408.pdf&amp;ei=f9TfUdf‐C6_T7AbRjICoDg&amp;usg=AFQjCNHXDsDiIJivPVumE_aFvjnvjMhqUw&amp;sig2=bouiXecktYUZw‐SPeLE22w&amp;bvm=bv.48705608,d.ZGU&amp;cad=rja (accessed 7 December 2013). [DOI: 10.3310/hta14080] ">Song 2010</a>). We adhered to best practice guidelines throughout the review process in terms of study selection, resolution of disagreements, data extraction and analysis. </p> </section> <section id="CD009019-sec-0087"> <h3 class="title" id="CD009019-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>Several previous reviews have meta‐analysed single‐inhaler maintenance and reliever therapy versus other recommended treatment strategies (<a href="./references#CD009019-bbs2-0018" title="AgarwalR , KhanA , AggarwalAN , GuptaD . Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta‐analysis. Monaldi Archives for Chest Disease2009;71(4):161‐9. [1122‐0643: (Print)] ">Agarwal 2009</a>; <a href="./references#CD009019-bbs2-0020" title="BatemanED , HarrisonTW , QuirceS , ReddelHK , BuhlR , HumbertM , et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. http://respiratory‐research.com/content/12/1/38 (accessed 7 December 2013). [DOI: 10.1186/1465‐9921‐12‐38] ">Bateman 2011</a>; <a href="./references#CD009019-bbs2-0027" title="Cates ChristopherJ , KarnerC . Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD007313.pub3; CD007313] ">Cates 2013</a>; <a href="./references#CD009019-bbs2-0030" title="EdwardsSJ , vonMaltzahnR , NayaIP , HarrisonT . Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials. International Journal of Clinical Practice2010;64(5):619‐27. [1742‐1241: (Electronic)] ">Edwards 2010</a>). As in this review, all found that exacerbation rates were reduced with SiT compared with usual care (<a href="./references#CD009019-bbs2-0027" title="Cates ChristopherJ , KarnerC . Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD007313.pub3; CD007313] ">Cates 2013</a>), ICS alone at equivalent or higher doses (<a href="./references#CD009019-bbs2-0018" title="AgarwalR , KhanA , AggarwalAN , GuptaD . Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta‐analysis. Monaldi Archives for Chest Disease2009;71(4):161‐9. [1122‐0643: (Print)] ">Agarwal 2009</a>; <a href="./references#CD009019-bbs2-0027" title="Cates ChristopherJ , KarnerC . Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD007313.pub3; CD007313] ">Cates 2013</a>) and fixed‐dose ICS/LABA combinations (<a href="./references#CD009019-bbs2-0018" title="AgarwalR , KhanA , AggarwalAN , GuptaD . Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta‐analysis. Monaldi Archives for Chest Disease2009;71(4):161‐9. [1122‐0643: (Print)] ">Agarwal 2009</a>; <a href="./references#CD009019-bbs2-0020" title="BatemanED , HarrisonTW , QuirceS , ReddelHK , BuhlR , HumbertM , et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. http://respiratory‐research.com/content/12/1/38 (accessed 7 December 2013). [DOI: 10.1186/1465‐9921‐12‐38] ">Bateman 2011</a>; <a href="./references#CD009019-bbs2-0030" title="EdwardsSJ , vonMaltzahnR , NayaIP , HarrisonT . Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials. International Journal of Clinical Practice2010;64(5):619‐27. [1742‐1241: (Electronic)] ">Edwards 2010</a>). This reinforces the validity of our findings and suggests that SiT might induce better control of inflammation in asthma, thanks to low additional doses of inhaled steroids in combination with formoterol only when really needed because of the participant's clinical condition. </p> <p>Evidence regarding the benefits of SiT for hospitalisation has been mixed. This review obtained evidence that is in line with evidence reported by <a href="./references#CD009019-bbs2-0018" title="AgarwalR , KhanA , AggarwalAN , GuptaD . Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta‐analysis. Monaldi Archives for Chest Disease2009;71(4):161‐9. [1122‐0643: (Print)] ">Agarwal 2009</a> and <a href="./references#CD009019-bbs2-0030" title="EdwardsSJ , vonMaltzahnR , NayaIP , HarrisonT . Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials. International Journal of Clinical Practice2010;64(5):619‐27. [1742‐1241: (Electronic)] ">Edwards 2010</a>, which used similar comparators. <a href="./references#CD009019-bbs2-0027" title="Cates ChristopherJ , KarnerC . Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD007313.pub3; CD007313] ">Cates 2013</a> did not find that SiT reduced hospitalisations, but in this review, SiT was compared with ICS alone or with current best practice. Our review demonstrates a reduction in exacerbations requiring hospitalisation or an ER visit, although we were able to analyse data for the two definitions only separately. </p> <p><a href="./references#CD009019-bbs2-0028" title="CzarneckaK , ChapmanKR . The clinical impact of single inhaler therapy in asthma. Clinical and Experimental Allergy2012;42(7):1006‐13. [1365‐2222: (Electronic)] ">Czarnecka 2012</a> concluded that although single‐inhaler therapy reduces exacerbations, it is associated with 'poor symptom control of asthma'. This is not in line with the findings of this review or with the conclusions of other reviews, which tend to report no evidence of statistical differences in various symptom measures or spirometry compared with other treatment strategies. Although this should not be interpreted as evidence of equivalent efficacy, it suggests that evidence is insufficient to permit review authors to state the superiority of SiT or the fixed‐dose comparison for these outcomes. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009019-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009019-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009019-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Cates plot: In the control group, 10 of 100 people had an exacerbation requiring oral steroids over eight months compared with eight (95% CI seven to nine) of 100 in the SiT group." data-id="CD009019-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Cates plot: In the control group, 10 of 100 people had an exacerbation requiring oral steroids over eight months compared with eight (95% CI seven to nine) of 100 in the SiT group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Cates plot: In the control group, five of 100 people had an exacerbation requiring hospitalisation or an ER visit over eight months, compared with four (95% CI three to five) of 100 in the SiT group." data-id="CD009019-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Cates plot: In the control group, five of 100 people had an exacerbation requiring hospitalisation or an ER visit over eight months, compared with four (95% CI three to five) of 100 in the SiT group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 1 Participants with exacerbations requiring oral steroids." data-id="CD009019-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 1 Participants with exacerbations requiring oral steroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 2 Participants with serious adverse events." data-id="CD009019-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 2 Participants with serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 3 Participants with severe exacerbations (hospitalisation or ER visit)." data-id="CD009019-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 3 Participants with severe exacerbations (hospitalisation or ER visit). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 4 Morning PEF (L/min)." data-id="CD009019-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 4 Morning PEF (L/min).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 5 Evening PEF (L/min)." data-id="CD009019-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 5 Evening PEF (L/min).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 6 FEV1 predose (mL)." data-id="CD009019-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 6 FEV<sub>1</sub> predose (mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 7 Rescue medication puffs required per day." data-id="CD009019-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 7 Rescue medication puffs required per day. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 8 Symptoms (ACQ‐5)." data-id="CD009019-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 8 Symptoms (ACQ‐5).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 9 Symptom‐free days (%)." data-id="CD009019-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 9 Symptom‐free days (%).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 10 Nocturnal awakenings (%)." data-id="CD009019-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 10 Nocturnal awakenings (%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 11 Quality of life AQLQ(S)." data-id="CD009019-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 SiT versus higher‐dose ICS/LABA + SABA, Outcome 11 Quality of life AQLQ(S).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 (Sensitivity analysis – Baseline severity), Outcome 1 Participants with exacerbations requiring oral steroids." data-id="CD009019-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 (Sensitivity analysis – Baseline severity), Outcome 1 Participants with exacerbations requiring oral steroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 (Sensitivity analysis – Baseline severity), Outcome 2 Participants with serious adverse events." data-id="CD009019-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 (Sensitivity analysis – Baseline severity), Outcome 2 Participants with serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 (Sensitivity analysis – Baseline severity), Outcome 3 Participants with severe exacerbations (hospitalisation or ER visit)." data-id="CD009019-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 (Sensitivity analysis – Baseline severity), Outcome 3 Participants with severe exacerbations (hospitalisation or ER visit). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 (Sensitivity analysis – Blinding), Outcome 1 Participants with exacerbations requiring oral steroids." data-id="CD009019-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 (Sensitivity analysis – Blinding), Outcome 1 Participants with exacerbations requiring oral steroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 (Sensitivity analysis – Blinding), Outcome 2 Participants with serious adverse events." data-id="CD009019-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 (Sensitivity analysis – Blinding), Outcome 2 Participants with serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009019-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/urn:x-wiley:14651858:media:CD009019:CD009019-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_t/tCD009019-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 (Sensitivity analysis – Blinding), Outcome 3 Participants with severe exacerbations (hospitalisation or ER visit)." data-id="CD009019-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 (Sensitivity analysis – Blinding), Outcome 3 Participants with severe exacerbations (hospitalisation or ER visit). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/media/CDSR/CD009019/image_n/nCD009019-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009019-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">SiT for maintenance/relief compared with higher‐dose ICS/LABA + SABA for chronic asthma in adults and children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>SIT for maintenance/relief compared with ICS/LABA combination at a higher fixed dose + SABA for chronic asthma in adults and children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Studies recruited adults and adolescents aged 12 and older with chronic asthma<br/> <b>Intervention:</b> SiT for maintenance and relief<br/> <b>Comparison:</b> higher‐dose ICS/LABA as maintenance + SABA as relief </p> <p><b>Setting</b>: community </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> <p><b>Follow‐up calculated as weighted means, with range</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Overall heterogeneity and subgroup differences (ICS/LABA combination in control group)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Higher‐dose ICS/LABA+ SABA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SiT for maintenance/relief</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>People with exacerbations requiring hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AstraZeneca could not provide data for hospitalisations separate to ER visits</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Patients with exacerbations requiring oral steroids</b> <br/> Follow‐up: eight months (six to 12) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Eight per 100</b> </p> <p>(seven to nine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.75</b> </p> <p>(0.65 to 0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9096</p> <p>(four studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I<sup>2</sup> = 0%; P value 0.82 </p> <p>Subgroup differences (P value 0.45)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with serious adverse events</b> <br/> Follow‐up: eight months (six to 12) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Four per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Four per 100</b> <br/> (three to five) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.92</b> <br/> (0.74 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9130<br/> (four studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I<sup>2</sup> = 0%; P value 0.98 </p> <p>Subgroup differences (P value 0.88)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with severe exacerbations (requiring hospitalisation <i>or</i> ER visit)</b> <br/> Follow‐up: eight months (six to 12) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Five per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Four per 100</b> <br/> (three to five) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.72</b> <br/> (0.57 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7768<br/> (three studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I<sup>2</sup> = 0%; P value 0.66 </p> <p>Subgroup differences (P value 0.21)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; <b>ICS/LABA:</b> inhaled corticosteroid/long‐acting beta<sub>2</sub>‐agonist combination inhaler; <b>SABA:</b> short‐acting beta<sub>2</sub>‐agonist; <b>SiT:</b> single‐inhaler therapy with budesonide/formoterol inhaler. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Wide confidence intervals, downgraded once for imprecision.</p> <p>Although issues with blinding were noted in two of the studies, and one study recruited a less severe population, sensitivity analyses did not change the main results, so outcomes were not downgraded. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">SiT for maintenance/relief compared with higher‐dose ICS/LABA + SABA for chronic asthma in adults and children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009019-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Age range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> % Male</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> FEV<sub>1</sub> % predicted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Mean baseline daily ICS (BDP)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) SiT</p> <p>2) Flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 (range 45 to 144)</p> <p>71 (range 45 to 222)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>705 (range 250 to 1600)</p> <p>720 (range 200 to 2000)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) SiT</p> <p>2) Flut/salm</p> <p>3) Bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (SD 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>43</p> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> <p>73</p> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>740 (SD 240)</p> <p>744 (SD 230)</p> <p>750 (SD 262)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) SiT</p> <p>2) Bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (SD 19)</p> <p>45 (SD 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐87</p> <p>12‐95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95 (SD 18)</p> <p>97 (SD 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>636 (SD 293)</p> <p>650 (SD 315)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) SiT</p> <p>2) Flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐80</p> <p>12‐84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73 (range 39 to 115)</p> <p>73 (range 28 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888 (range 500 to 2000)</p> <p>881 (range 400 to 3000)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Where only one line of data appears in a cell, data were not available for individual trial arms but rather for the whole study<br/> population. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009019-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of the interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b> Study ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> Single‐inhaler therapy (budesonide/formoterol)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> Comparison ICS/LABA total planned daily dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>Planned daily maintenance schedule</i> <br/> (with reliever dose)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>Total ICS received per</i> <br/> <i>day (mean, BDP</i> μ<i>g)</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>Planned daily maintenance schedule</i> <br/> (with reliever)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b><i>Total ICS received per</i> <br/> <i>day (mean, BDP</i> μ<i>g)</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0001" title="BousquetJ , BouletLP . Budesonide/formoterol as maintenance and reliever therapy in uncontrolled asthma compared with high dose salmeterol/fluticasone: the AHEAD double blind study [Abstract]. European Respiratory Journal2007;30 Suppl 51:358s [P2156]. BousquetJ , BouletLP , PetersMJ , MagnussenH , QuiralteJ , Martinez‐AguilarNE , et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high‐dose salmeterol/fluticasone. Respiratory Medicine2007;101(12):2437‐46. BousquetJ , MiravitllesM , WirenA . Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high dose salmeterol fluticasone treatment [Abstract]. European Respiratory Journal2007;30 Suppl 51:193s [P1185]. CisnerosC , QuiralteJ , CapelM , CasadoMA , MellstromC . Cost‐effectiveness analysis of budesonide/formoterol in the maintenance treatment and as‐needed (Symbicort SMART) versus salmeterol/fluticasone plus terbutaline in the treatment of persistent asthma in Spain. Pharmacoeconomics2010;7(4):163‐75. Lin DrJ , ChenP , ZhouX , SunT , XieC , XiuQ , et al. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chinese Medical Journal2012;125(17):2994‐3001. [0366‐6999] NCT00242775 . Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg &amp; Terbutaline Turbuhaler® 0.4 mg. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890C00002 ; clinicaltrials.gov study ID: NCT00242775] PetersM , BousquetJ . Episodic high reliever use with budesonide/formoterol; maintenance and reliever therapy confers added protection against asthma exacerbations [Abstract]. European Respiratory Journal2007;30 Suppl 51:615s [P3613]. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Bousquet 2007 [AHEAD]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640/18 μg<br/> (160/4.5 as needed) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flut/salm 1000/100 μg<br/> (terbutaline) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009019-bbs2-0002" title="AstraZenecaSD . Comparison of the efficacy and safety of one inhalation of Symbicort® Turbuhaler® 160/4.5 µg bid plus as‐needed with two inhalations of SeretideTM EvohalerTM 25/125 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed, and one inhalation of Symbicort® Turbuhaler® 320/9 µg bid plus Terbutaline Turbuhaler® 0.4 mg as‐needed. A 6‐month, randomised, double‐blind, double‐dummy, parallel‐group, active‐controlled, multi‐centre, phase IIIB study in adult and adolescent asthmatic patients. www.astrazenecaclinicaltrials.com/‎ (accessed 26 April 2012). BoonsawatW . Cost‐effectiveness of budesonide/formoterol maintenance and rescue therapy in Thailand. Asian Biomedicine2010;4(4):571‐8. BuhlR , KunaP . Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as needed use? [Abstract]. European Respiratory Journal2007;30 Suppl 51:617s [P3620]. KunaP . Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged &gt;=16 years with asthma: post hoc analysis of a randomized, double‐blind study. Clinical Drug Investigation2010;30(9):565‐79. KunaP , PeetersM , BuhlR . Budesonide/formoterol for maintenance and relief vs higher dose ICS/LABA therapy outcomes in patients symptomatic on high dose inhaled corticosteroids (HDICS) [Abstract]. European Respiratory Journal2007;30 Suppl 51:357s [P2152]. KunaP , PetersJ , BuhlR . Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone [Abstract]. European Respiratory Journal2006;28 Suppl 50:205s [P1228]. KunaP , PetersMJ , ManjraAI , JorupC , NayaIP , Martinez‐JimenezNE , et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. International Journal of Clinical Practice2007;61(5):725‐36. MillerE , FitzGeraldJM . Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies ‐ a Canadian economic evaluation. Canadian Journal of Clinical Pharmacology2008;15(2):e165‐76. PriceD , WirenA , KunaP . Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost saving versus higher maintenance dose of B/F or salmeterol/fluticasone (S/F) [Abstract]. European Respiratory Journal2006;28 Suppl 50:214s [P1274]. PriceD , WirenA , KunaP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology2007;62(10):1189‐98. TamminenK , LaineJ , SoiniE , MartikainenJ , KankaanrantaH . Cost‐effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Current Medical Research and Opinion2008;24(12):3453‐61. WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Kuna 2007 [COMPASS]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>320/9 μg<br/> (160/4.5 as needed) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flut/salm 500/100 μg<br/> (terbutaline) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bud/form 640/18 μg<br/> (terbutaline) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0003" title="NCT00259766 . SHARE ‐ Symbicort and Health Economics in a Real Life Evaluation. www.clinicaltrials.gov (accessed 24 April 2012). [AstraZeneca study ID: D5890L00001; clinicaltrials.gov study ID: NCT00259766] StallbergB , EkstromT , NeijF , OlssonP , SkooghBE , WennergrenG , et al. A real‐life cost‐effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Medicine2008;102(10):1360‐70. StallbergB , LofdahlCG , SkooghBE , WennergrenG , OlssonP , NeijF , et al. Budesonide/formoterol maintenance and reliever therapy effective treatment at a lower cost [Abstract]. European Respiratory Society Annual Congress; 2008 Oct 4‐8; Berlin. 2008:[4424]. ">Stallberg 2008 [SHARE]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320/9 or 160/9 μg based on previous ICS use</p> <p>(160/4.5 or 80/4.5 as needed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bud/form 640/18 or 320/18 μg<br/> (terbutaline) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>574</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009019-bbs2-0004" title="D'UrzoA , VogeimeierC , JaspalM , MerinoJM , BouletS . Symbicort (budesonide/formoterol) for both maintenance and relief reduces the exacerbation burden compared with titration of seretide (salmeterol/fluticasone) in patients with asthma, a real life study [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:[B35] [Poster: G24]. JohanssonG , AndreassonEB , LarssonPE , VogelmeierCF . Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics2006;24(7):695‐708. JohanssonG , LarssonPER , AndreassonE . Maintenance plus as needed budesonide/formoterol is cost effective compared with dose titrated salmeterol/fluticasone [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 432. MillerE , SearsMR , McIvorA , LiovasA . Canadian economic evaluation of budesonide‐formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Canadian Respiratory Journal2007;14(5):269‐75. VogelmeierC , D'UrzoA . Maintenance plus as‐needed budesonide/formoterol vs salmeterol/fluticasone in a real‐life setting [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 2770. VogelmeierC , D'UrzoA , JaspalM , MerinoJM , JohanssonG , BouletS . Symbicort for both maintenance and relief reduces exacerbations compared with a titration of Seretide (Advair) in patients with asthma: a real life study [Abstract]. American Thoracic Society International Conference 2005; May 20‐25; San Diego. 2005:[C33] [Poster: F67]. VogelmeierC , D'UrzoA , PauwelsR , MerinoJM , JaspalM , BoutetS , et al. Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal2005;26(5):819‐28. VogelmeierC , NayaI , EkelundJ . Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged &gt;=16 years) with asthma: a sub‐analysis of the COSMOS study. Clinical Drug Investigation2012;32(7):439‐49. [ES:1179‐1918: IL:1173‐2563] WickstromJ , DamN , MalmbergI , HansenBB , LangeP . Cost‐effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark ‐ Cost‐effectiveness analysis based on five randomised controlled trials. Clinical Respiratory Journal2009;3(3):169‐80. ">Vogelmeier 2005 [COSMOS]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640/18 μg<br/> (160/4.5 as needed) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flut/salm 500/100 μg<br/> (salbutamol) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1166</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of the interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/full#CD009019-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009019-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">SiT versus higher‐dose ICS/LABA + SABA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants with exacerbations requiring oral steroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9096</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.65, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.65, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.51, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants with serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.74, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.73, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.58, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants with severe exacerbations (hospitalisation or ER visit) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.57, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.51, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.58, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Morning PEF (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.46 [‐3.85, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.74 [‐4.55, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.7 [‐5.29, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Evening PEF (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐2.24, 2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [‐2.39, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.6 [‐5.06, 3.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 FEV<sub>1</sub> predose (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.35 [2.72, 35.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.06 [‐4.42, 44.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.75 [‐3.91, 41.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Rescue medication puffs required per day <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.27, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.35, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.15, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Symptoms (ACQ‐5) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.07, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.07, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Symptom‐free days (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.16 [‐2.99, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐3.47, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐4.23, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Nocturnal awakenings (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.08 [‐2.13, ‐0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐2.34, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐3.02, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Quality of life AQLQ(S) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">SiT versus higher‐dose ICS/LABA + SABA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009019-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">(Sensitivity analysis – Baseline severity)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants with exacerbations requiring oral steroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.64, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.65, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.43, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants with serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.73, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.73, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.45, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants with severe exacerbations (hospitalisation or ER visit) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.57, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.51, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.58, 1.57]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">(Sensitivity analysis – Baseline severity)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009019-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">(Sensitivity analysis – Blinding)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants with exacerbations requiring oral steroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.59, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.59, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.43, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants with serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.68, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.67, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.45, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants with severe exacerbations (hospitalisation or ER visit) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.56, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 SiT versus higher flut/salm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.49, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 SiT versus higher bud/form</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.58, 1.57]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">(Sensitivity analysis – Blinding)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009019.pub2/references#CD009019-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009019.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009019-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009019-note-0004">فارسی</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009019\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009019\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009019\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009019\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009019\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009019.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009019.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009019.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009019.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009019.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717945351"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009019.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717945354"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009019.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc4506b3b9377',t:'MTc0MDcxNzk0NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 